Navigation Links
Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Date:3/7/2008

NEW HAVEN, Conn., March 7 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq Capital Market: VION) today announced that it had received notification from NASDAQ that the Company had regained compliance with Marketplace Rule 4310(c)(4) since the closing bid price of its Common Stock had traded at $1.00 per share or greater for at least ten consecutive business days.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations,
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... (PRWEB) March 01, 2015 Theme and ... new transition pack for Final Cut Pro ... accordion style transitions to any FCPX editors project.” Said ... our users the tools needed to easily drag and ... The user gets many different controls over the parameters ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... The Heart Fit Clinic started doing External Counterpulsation ... The Heart Fit Clinic is also selling the machines ... The goal is to scale the business to help ... buy External Counterpulsation machines can be difficult process. ... process and achieve the desired results. , The ...
(Date:2/28/2015)... February 28, 2015 Vancouver personal injury lawyers ... claims are affected by time limits. They stated that in ... person’s claim or even nullify it. Many a time, delays ... a client’s rights under BC law. As a result, experts ... by accidents should consult a personal injury lawyer in order ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation (Meso ... Symposium on Malignant Mesothelioma on Monday, March 2. The ... Bethesda in Bethesda, Maryland. The following award recipients will ... the mission to cure mesothelioma. , The Klaus Brauch ... Miriam Ratner. Miriam runs the Meso Foundation’s monthly spousal ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
... came to St. Louis Children,s Hospital in the summer of ... pressure in his lungs. Washington University physicians and surgeons ... fast to save his life. They collaborated to make several ... use of an artificial lung in a toddler. Their ...
... THURSDAY, June 16 (HealthDay News) -- No long-term decrease in ... officers from the New York Police Department,s Emergency Services Unit ... Trade Center, according to a new study. Researchers analyzed ... who responded to the attack and found that most had ...
... HealthDay Reporter , THURSDAY, June 16 (HealthDay News) -- The ... popular diabetes drug Actos (pioglitazone) may increase the risk of ... The agency,s warning comes five days after Germany and France ... in a class of drugs called thiazolidinediones, the only other ...
... University of Texas Health Science Center at Houston (UTHealth) could ... produce the type of fat ringing the waists of millions. ... Cell Stem Cell . The scientists have developed ... day could aid in the delivery of drugs that slow ...
... 16 (HealthDay News) -- Researchers have pinpointed the brain regions ... one of the most fundamental aspects of self-awareness. The ... of the brain that create a unified view of the ... body, according to the study published online June 16 in ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, June 16 ... grades in high school and the beginning years of college, ... as they adopt more traditional sleeping schedules, a change occurs. ... Peszka, an associate professor of psychology at Hendrix College in ...
Cached Medicine News:Health News:Washington University surgeons successfully use artificial lung in toddler 2Health News:Washington University surgeons successfully use artificial lung in toddler 3Health News:Washington University surgeons successfully use artificial lung in toddler 4Health News:Lung Health of Police Responders From 9/11 Called 'Encouraging' 2Health News:Diabetes Drug Actos May Raise Risk for Bladder Cancer: FDA 2Health News:Diabetes Drug Actos May Raise Risk for Bladder Cancer: FDA 3Health News:New stem cell research could aid in battle against bulging waistlines 2Health News:Scientists Pinpoint Parts of Brain That Help People Recognize Themselves 2Health News:Night Owls' Poor Sleep Habits Can Hurt Grades 2Health News:Night Owls' Poor Sleep Habits Can Hurt Grades 3
(Date:2/27/2015)... 27, 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... that it acquired Bionik Laboratories, Inc., a ... sale to qualified accredited investors of units consisting of ... of approximately $6.2 million. Shares of the Company,s common ... Markets under the symbol "DWTPD" until FINRA,s approval of ...
(Date:2/27/2015)... , Feb. 27, 2015  Two mass ... in applications as their effectiveness is established, ... Information.  Kalorama Information says that while mass ... most powerful tool in proteomic biomarker discovery ... through its traditional techniques has struggled to ...
(Date:2/26/2015)... February 27, 2015 RnRMarketResearch.com ... market research report to its store. This report ... therapeutic pipeline. The report "Corneal Ulcers - Pipeline ... therapeutic development for Corneal Ulcers. Corneal Ulcers are ... bacterial infections, viral infections & fungal infections. The ...
Breaking Medicine Technology:Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
... Ill., Feb. 8, 2011 Sysmex America, Inc. ... Service Agreement with PeaceHealth, a not-for-profit integrated healthcare ... group clinics and laboratories located in Alaska, Washington ... the agreement ensures either the installation of a ...
... MedShape Solutions, Inc., the industry ... announced the introduction and first human clinical use ... fixation device that simplifies and improves soft tissue ... surgery. After receiving 510(k) clearance from the U.S. ...
Cached Medicine Technology:PeaceHealth Standardizes Hematology Operations With Sysmex 2PeaceHealth Standardizes Hematology Operations With Sysmex 3MedShape Solutions, Inc. Announces Breakthrough in ACL Reconstruction 2MedShape Solutions, Inc. Announces Breakthrough in ACL Reconstruction 3
... Tri-Active is the result of DEKA ... combination of three different methods capable ... your skin. This treatment is designed ... cellulite through the combined action of ...
... Smartepil II Plus is the latest evolution ... fast, safe and reliable system for epilation ... preset protocols in its modern software, Smartepil ... vascular treatments in full respect of the ...
This instrument measures intraocular pressure without,contacting. Alignment is performed semi-automatically....
The convenience of safe and precise Patient Controlled Analgesia in a flexible system designed with advanced technology. This is progressive, innovative, and effective pain management in a sophistica...
Medicine Products: